Loading company…
Ten63 Therapeutics uses computational models to discover small-molecule drugs for previously undruggable targets.
Founded in 2018 and based in Durham, North Carolina, Ten63 Therapeutics develops the Copper platform, which uses physical models to identify drug candidates for difficult targets. In February 2026, it raised USD 22 million from Black Opal Ventures, Cape Fear BioCapital, Chugai Venture Fund, Duke Capital Partners, Gates Foundation Trust, K5 Global, Panorama, RYSE Asset Management, SF Holdings, Alexandria Venture Investments, Draper, Hatteras Venture Partners, Morpheus Ventures, and Yosemite Management.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in